BioNxt Solutions开发出可溶解的硫酸盐薄膜,提供了一种新的非侵入性治疗方案。 BioNxt Solutions develops dissolvable film for Semaglutide, offering a new non-invasive treatment option.

BioNxt Solutions Inc.成功地完成了对Semaglutide口服溶解薄膜的概念验证试验,在迅速解体和良好的机械性能方面显示出有希望的结果。 BioNxt Solutions Inc. has successfully completed proof-of-concept trials for its Semaglutide oral dissolvable film, showing promising results in rapid disintegration and good mechanical properties. 该公司计划提交专利申请,并打算在2026年下半年开始试点临床研究。 The company plans to file a patent and aims to begin a pilot clinical study in the second half of 2026. 这一发展为目前治疗2型糖尿病和肥胖症的注射和药片选择提供了潜在的非侵入性替代办法。 This development offers a potential non-invasive alternative to current injectable and tablet options for treating type 2 diabetes and obesity.